What were the relative and absolute all-cause mortality risk reduction figures for the MADIT II patient population?
The patient population of the MADIT II trial was assigned in a 3:2 ratio to receive Guidant implantable cardioverter defibrillator (ICD) therapy and conventional medical therapy, as directed by a physician, or conventional therapy alone. MADIT II results demonstrated a 31% relative risk reduction in the Guidant ICD therapy group.
